Literature DB >> 22407909

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.

Hee Yeon Kim1, Jong Young Choi, Chang Wook Kim, Si Hyun Bae, Seung Kew Yoon, Young Joon Lee, Sung Eun Rha, Young Kyoung You, Dong Goo Kim, Eun Sun Jung.   

Abstract

The aim of this study was to investigate the role of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) in predicting the histological grade of hepatocellular carcinoma (HCC) according to the hepatic function. Eighty-one consecutive patients with 122 histologically proven HCCs who underwent Gd-EOB-DTPA-enhanced MRI before resection (45 HCCs in 42 patients) or transplantation (77 HCCs in 39 patients) were analyzed retrospectively. We calculated the relative enhancement ratios (RER), which is the ratio of the relative intensity of a tumor versus the surrounding parenchyma on hepatobiliary phase images to the relative intensity on unenhanced MRI scans. We then analyzed the correlation between the RER and the tumor differentiation grade in patients with various degrees of hepatic function. The degree of tumor enhancement, which included the precontrast relative intensity ratio (RIR), the postcontrast RIR, and the RER, for well-differentiated (WD) HCCs was significantly higher than the degree of tumor enhancement for moderately differentiated and poorly differentiated (PD) HCCs (P = 0.001 and P = 0.001, respectively, for precontrast RIRs; P < 0.001 and P < 0.001, respectively, for postcontrast RIRs; and P = 0.01 and P = 0.001, respectively, for RERs). In a subgroup analysis based on liver function, the correlation between the histological grade and the enhancement ratio was demonstrated only in the group of patients with Child-Pugh class A cirrhosis. The accuracy of postcontrast RIRs for predicting WD and PD HCCs was favorable; the areas under the receiver operating characteristic curves were 0.896 [95% confidence interval (CI) = 0.817-0.974] and 0.769 (95% CI = 0.658-0.879), respectively. In conclusion, the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI may help to predict the differentiation of HCCs, especially in HCC patients with Child-Pugh class A cirrhosis before liver transplantation or resection.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407909     DOI: 10.1002/lt.23426

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  18 in total

Review 1.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

2.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

Review 3.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

4.  Prediction of histological grade of hepatocellular carcinoma using quantitative diffusion-weighted MRI: a retrospective multivendor study.

Authors:  Yusuke Ogihara; Yoshio Kitazume; Yoshihiro Iwasa; Shinichi Taura; Yoshiro Himeno; Tomo Kimura; Seishi Sawano; Shigehiko Terada; Minoru Tanabe; Yukihisa Saida; Ukihide Tateishi
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

Review 5.  Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging.

Authors:  Jens Ricke; Max Seidensticker; Konrad Mohnike
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

6.  Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma.

Authors:  Yingfan Mao; Jincheng Wang; Yong Zhu; Jun Chen; Liang Mao; Weiwei Kong; Yudong Qiu; Xiaoyan Wu; Yue Guan; Jian He
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

7.  Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Authors:  Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 8.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

9.  Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis.

Authors:  Hee Yeon Kim; Jong Young Choi; Chung-Hwa Park; Myeong Jun Song; Do Seon Song; Chang Wook Kim; Si Hyun Bae; Seung Kew Yoon; Young Joon Lee; Sung Eun Rha
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

Review 10.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.